WO2025257588 - CD16A/TUMOR ANTIGEN POLYSPECIFIC BINDER FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR RESISTANCE
National phase entry is expected:
Publication Number
WO/2025/257588
Publication Date
18.12.2025
International Application No.
PCT/IB2024/055675
International Filing Date
10.06.2024
Title **
[English]
CD16A/TUMOR ANTIGEN POLYSPECIFIC BINDER FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR RESISTANCE
[French]
LIANT POLYSPÉCIFIQUE D'ANTIGÈNE DE CD16A/TUMEUR DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE LA RÉSISTANCE À UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE
Applicants **
AFFIMED GMBH
Inventors
RAJKOVIC, Erich
DULAT, Holger
MORALES-ESPINOSA, Daniela
PAHL, Jens
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3045 | |
| EPO | Filing, Examination, Granting | 21249 | |
| Japan | Filing, Examination, Granting | 2858 | |
| South Korea | Filing, Examination, Granting | 3317 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
39,209
Contact Us
Abstract[English]
Methods are disclosed for the treatment of cancer in a subject, wherein the subject is, or is predicted to be, resistant to immune checkpoint inhibitor (ICI) cancer treatment. A polyspecific binding molecule that binds to CD16A on innate immune cells and a tumor antigen, such as EGFR or FOLR1, on tumor cells, is administered to the resistant subject. The polyspecific binding molecule can sensitize the tumor towards treatment with an ICI, such as a PD-L1 or PD-1 inhibitor.[French]
L'invention concerne des méthodes pour le traitement du cancer chez un sujet, le sujet étant, ou étant prédit comme étant, résistant au traitement du cancer par inhibiteur de point de contrôle immunitaire (ICI). Une molécule de liaison polyspécifique qui se lie à CD16A sur des cellules immunitaires innées et un antigène tumoral, tel que EGFR ou FOLR1, sur des cellules tumorales, est administrée au sujet résistant. La molécule de liaison polyspécifique peut sensibiliser la tumeur vis-à-vis d'un traitement avec un ICI, tel qu'un inhibiteur de PD-L1 ou de PD-1.